Ontacad, Inc.'s original offering opened on December 29, 2020 and was completed on March 1, 2021. Except for the Updates section which may contain more recent information, the information on this page was accurate as of March 1, 2021.

Ontacad, Inc.

Ontacad is looking to disrupt a $500 billion market through its Software as a Service (SaaS) product that converts scientific and medical software and equipment user guides to video-tutorials to assist clients saving time and money.

Introduction

Ontacad is a global health-tech startup that converts medical and scientific software and instrument user guides to video tutorials. Through its patent-pending technology, Ontacad is designed to help medical and scientific software and equipment providers save time and money by reducing customer acquisition cost, increasing customer lifetime value, and boosting revenues. Ontacad is an innovative female co-founded business that provides opportunities for impact investment.

Deal Highlights

We have:

  • Patent-pending technology
  • An early-mover-advantage
  • 150 clients
  • 5 established strategic partnerships

We believe companies will find our product desirable. Ontacad has developed the beta product and five scientific software providers want to place their products on our marketplace. Ontacad has 150 registered users at present who are using our marketplace solution. If we achieve our vision, we believe Ontacad has the potential to become a highly valuable healthcare technology startup.

Problem

International scientific and medical instruments and software providers spend millions of dollars to print user guides and manuals that include thousands of pages for their products. Scientific and medical instrument and software documentation (user guides and manuals) suffer from several potential problems:

  • Expensive
  • Time-consuming
  • High documentation cost
  • Hard to read
  • Vague
  • Complex
  • Outdated

Scientific and medical software training has a number of potential problems:

  • Expensive, scientific software training costs thousands of dollars per user
  • Online course platforms provide low content
  • Limited access to scientific software courses in one marketplace
Problem

Solution

Ontacad offers a Software as a Service (SaaS) product for scientific and medical instruments and software providers. The product helps:

  • to convert user guides for scientific and medical instruments and software to video tutorials.
  • to provide online shopping , online training, and prompt support for its customers, anytime and anywhere.
Solution
Product

Business Model

Ontacad uses a monthly subscription model to generate revenue. Scientific and medical software and equipment providers will pay $39, $79 per month for SaaS software, training, and prompt support.

Business model

Market

Market
Competition

Ontacad has a significant an opportunity to disrupt a $550 billion market and expand services to target scientific and medical instruments and software, in the US during the next two years.

Competitive advantages

Progress

  • Our technology is protected under “US patent pending”.
  • Strong tech and customer pipeline 150 registered users and highly favourable customer feedback.
  • Our team has strategic partnerships with 5 scientific software companies.

Team

Our team has healthcare and startup experience to lead innovative technology. We have worked on international projects in collaboration with organizations, such as the WHO and University Lille2 – France. We have worked as researchers at top healthcare and research organizations,such as the Egyptian Drug Authority that’s similar to the FDA. Medhat met Hanady during their postgraduate studies six years ago. We have established our private UK-based startup.Skillsuper is a platform to help academics and researchers learn all essential digital transformation skills.

Medhat Ahmed
CEO and Co-Founder

Data Scientist & Graphic Designer & Researcher, Chemistry, Assiut University.

Medhat is a Co-founder of Skillsuper®, the world's first all-in-one platform to develop future researchers and inventors at all levels. Previous healthcare experience at many national and international healthcare and research institutions such as Lille University-France. Serial entrepreneur. Recognized by media outlets including Digital Journal and D Magazine.

Hanady Elgamal
COO and Co-Founder

Researcher & Sales Specialist & Web Developer, Chemistry-Zoology, Helwan University.

Experienced Quality Control Auditor with a demonstrated history of working in the pharmaceutical industries and projects such WHO and EDA (like FDA in the USA). Hanady is a Co-founder of Skillsuper®, the world's first all-in-one platform to develop future researchers and inventors at all levels. Skilled in Microsoft Office, Web Development, Python, Sales, Soft Skills, Biotechnology, Management, scientific and medical instruments, and Healthcare.

Advisors and Investors

Derek Van Vliet
ALTS Capital Director

Use of Proceeds


If the offering's maximum amount of $100,003 is raised:

UseValue% of Proceeds
Sales and Marketing$76,00076.0%
General and Administration$19,10319.1%
Intermediary fees$4,9004.9%

Terms

This is an offering of Common Stock, under registration exemption 4(a)(6), in Ontacad, Inc.. This offering must raise at least $10,000 by March 1, 2021 at 11:59pm ET. If this offering doesn’t reach its target, then your money will be refunded. Ontacad, Inc. may issue additional securities to raise up to $100,003, the offering’s maximum.

If the offering is successful at raising the maximum amount, then the company’s implied valuation after the offering (sometimes called its post-money valuation) will be:

936,102 shares
×
$2.77 per share
$2,593,003implied valuation

Pitch Deck

arrows remove Created with Sketch.

Financials

SEC Filings

The Offering Statement is a formal description of the company and this transaction. It’s filed with the SEC to comply with the requirements of exemption 4(a)(6) of the Securities Act of 1933.

We’re also required to share links to each of the SEC filings related to this offering with investors.

Understand the Risks

Be sure to understand the risks of this type of investment. No regulatory body (not the SEC, not any state regulator) has passed upon the merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials or information posted herein. That’s typical for Regulation CF offerings like this one.

Neither Netcapital nor any of its directors, officers, employees, representatives, affiliates, or agents shall have any liability whatsoever arising from any error or incompleteness of fact or opinion in, or lack of care in the preparation or publication of, the materials and communication herein or the terms or valuation of any securities offering.

The information contained herein includes forward-looking statements. These statements relate to future events or to future financial performance, and involve known and unknown risks, uncertainties, and other factors, that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company’s control and which could, and likely will, materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

More Info

Updates

  • Mar 2, 2021
    Primary offering finalized, selling 0 shares
    Sold 0 shares at $2.77 for a total of $0

Ask a Question

Proofread your comment before submitting: once it's posted, you can’t edit or delete it. For the fastest help with the web site, email help@netcapital.com instead of commenting.

Looking to raise capital?
We can help turn your friends, family and customers into investors.

Learn more

Interested in more investment opportunities?
Browse all offerings currently available.

See more